The success of antibody-based immunotherapeutics has revolutionized treatment options in many disease areas. Prerequisite for this achievement was to understand key mechanisms of the adaptive immune system and consequently employ this knowledge for creating novel therapeutics.
In contrast, the development of therapeutics exploiting the potential of innate immunity, which serves as a first line of defence against various pathogens, is still in its infancy.
Discovering certain target structures in patients suffering consequences from COVID-19 infections allowed us to recognize the potential of a specific type of innate antibodies and investigate their development into novel immunotherapeutics for a variety of chronic diseases.